
Opinion|Videos|March 27, 2025
The PDE4B Pathway: Exploring Nerandomilast’s Potential in Pulmonary Fibrosis Treatment
Author(s)Eric Cannon, PharmD, FAMCP
Eric Cannon, PharmD, FAMCP, discusses how the PDE4B pathway promotes inflammation and fibrosis in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) by regulating cAMP levels and fibroblast activity. Nerandomilast has shown promising anti-inflammatory and antifibrotic effects in preclinical models, with early clinical trials suggesting good tolerability and potential lung function stabilization. However, larger phase 3 trials with longer follow-up are needed to confirm efficacy, safety and impact on disease progression.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the significance of the PDE4B pathway in the pathogenesis of IPF and PPF?
- What has the data demonstrated with nerandomilast so far, and what future data is needed for this therapy?
- How do you envision nerandomilast fitting into treatment algorithms for patients with IPF and PPF?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
FDA approves combination therapy for blurry vision
3
Why the great pharma-MedTech divide is healthcare’s biggest miss
4
Medicaid expansion associated with lower overall breast cancer mortality
5



























